Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 8/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.48 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.47 |
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14207345 | 0.90 | GRIN2B (0.51) | GRIN2BHDAC1HDAC6HDAC8GRIN1 | |
| SCHEMBL8783707 | 0.88 | GRIN2B (0.67) | GRIN2BHDAC1HDAC6HDAC8GRIN1 | |
| SCHEMBL1883122 | 0.82 | GRIN2B (0.49) | GRIN2BHDAC1HDAC6HDAC8GRIN1 | |
| SCHEMBL29823333 | 0.82 | GRIN2B (0.49) | GRIN2BHDAC1HDAC6HDAC8GRIN1 | |
| Bromide SCHEMBL4550684 | 0.81 | GRIN2B (0.48) | GRIN2BHDAC1HDAC6HDAC8GRIN1 | |
| SCHEMBL4070370 | 0.80 | NAMPT (0.46) | GRIN2BHDAC1HDAC6HDAC8GRIN1 | |
| SCHEMBL7472586 | 0.79 | DRD2 (0.48) | GRIN2BGRIN1DRD2DRD3MAOA | |
| SCHEMBL8783295 | 0.79 | GRIN1 (0.54) | GRIN2BGRIN1DRD2DRD3 | |
| SCHEMBL8783223 | 0.78 | GRIN2B (0.50) | GRIN2BHDAC1HDAC6HDAC8GRIN1 | |
| SCHEMBL4066205 | 0.76 | HDAC1 (0.40) | GRIN2BHDAC1HDAC6HDAC8GRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090846-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | GENZYME CORPORATION | 2008-04-17 | — | — | US | disclosed |
| US-7312234-B2 | Chemokine receptor binding heterocyclic compounds | ANORMED (CA) | 2007-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090846-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | CCR2, CXCR3, ACKR3 | GRIN2B 686/4885HDAC1 1482/4885HDAC6 1162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.